Researchers have identified a novel method for predicting the effectiveness of KRAS G12C inhibitors in treating non-small cell lung cancer (NSCLC). The researchers developed a proximity ligation assay to measure RAS-RAF protein interactions inside cancer cells. Their findings revealed that stronger interactions between these proteins correlated with higher levels of active RAS signaling, which in turn made tumors more likely to respond to KRAS G12C inhibitors. This method was compared with other cancer activity markers, such as EGFR, which did not predict response to the inhibitors, highlighting RAS-RAF interactions as a more accurate biomarker.
The study’s results could revolutionize treatment strategies for patients with KRAS G12C–mutated NSCLC by providing physicians with a more reliable tool for selecting effective therapies. Researchers emphasized that measuring RAS-RAF interactions could lead to better-informed treatment decisions and improved patient outcomes. The proximity ligation assay could become a vital clinical tool, enabling more personalized cancer treatments and potentially enhancing survival rates for those with KRAS-mutated cancers.
Reference: The ASCO Post Staff. Predicting Response to KRAS G12C Inhibitors in NSCLC. The ASCO Post. Published February 4, 2025. Accessed February15, 2025. https://ascopost.com/news/february-2025/predicting-response-to-kras-g12c-inhibitors-in-nsclc/
Link: https://ascopost.com/news/february-2025/predicting-response-to-kras-g12c-inhibitors-in-nsclc/
